截至2025年5月20日，上证指数收涨0.38%，报3380.48点；深证成指收涨0.77%，报10249.17点；创业板指收涨0.77%，报2048.46点；两市总成交额1.17万亿 元，连续19日超万亿。 行业热度看，文娱用品表现亮眼，当日大涨5.31%；动物保健、饰品紧随其后，分别上涨4.82%、4.07%。 截至今日收盘，全市场共计1041只非货ETF上涨，上涨比例达到92%。国证港股通创新药指数上涨3.65%，港股通创新药ETF工银、港股通创新药ETF、港股 创新药ETF，分别上涨5.13%、4.81%、4.48%；中证港股通创新药指数上涨3.62%，港股创新药50ETF、港股创新药ETF基金，分别上涨5.24%、5.07%；恒生 生物科技指数上涨3.02%，恒生生物科技ETF上涨4.40%。 | 排名 | 证券代码 | 证券名称 | 涨幅 | 基金管理人 | 投资 | | --- | --- | --- | --- | --- | --- | | l | 513780.SH | 港股创新药50ETF | 5.24% | 景顺长城基金 | 股票 | | 2 | 513120.SH | 港股创新药ET ...

三连跌后，港股终于迎来反弹。 周二，港股三大指数高开高走，市场热点轮动加速，生物医药、创新药等板块发起强势猛攻。 | ● 热力图 ○ 列表 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | Wind香港概念板块指数 | | | Wind香港二级行业指数 | | | | | | 影视传媒 | 抗肿瘤 | 创新药 | 本地券商 | 黄金珠宝 | Wind香港电气设 Wind香港医药生 Wind香港家庭用 Wind香港硬件设 Wind香港传 | | | | | | 5.73% | 4.96% | 4.82% | 4.69% | 4.40% | 13.40% | 4.05% | 3.84% | 2.48% | 1.59% | | 智能家居 | 武汉本地 | 生物医疗 | CRO | 智能终端 | Wind香港汽车与 Wind香港电信服 Wind香港环保II Wind香港有色金 Wind香港家中 | | | | | | 3.82% | 3.80% | 3.75% | 3.43% | 3.38% ...

消息面上，5月20日，港股创新药企三生制药与海外辉瑞公司签订重大许可协议，授予辉瑞在全球（不 包括中国内地）独家开发、生产及商业化双抗的权利。根据协议，三生制药将获得12.5亿美元首付款， 并可能获得高达48亿美元的里程碑付款，以及双位数百分比的销售提成。这一交易再次刷新了国产创新 药出海首付款金额纪录。近期创新药行业利好不断。2025年第一季度，中国创新药license-out交易已有 41起，总金额达369.29亿美元，仅3个月已接近2023年全年水平。 相关产品：港股创新药ETF（159567）、创新药ETF（159992） 大而全：创新药ETF（159992）跟踪创新药指数，该指数布局创新药产业链龙头企业，既汇聚全球CXO 龙头企业，又包含国内仿创药企龙头，有望同时受益于AI赋能创新药、国产创新药出海、针对高价创 新药的医保丙类目录出台等。 国元证券认为，上周医药板块受特朗普宣布将推动美国处方药价格与"其他发达国家"对标政策影响，创 新药细分领域出现回调。特朗普提出行政令计划，旨在使美国药价下降30%-80%，并允许患者直接从制 造商购买药物，绕过中间商。然而，分析指出该政策实施难度较大，美国医药市场 ...

每经记者｜刘明涛 每经编辑｜彭水萍 今日上午，港股创新药板块全线大幅上涨，多只相关ETF半日涨幅在5%左右，其中，港股创新药ETF（513120）半日成交金额高达28.28亿元，交投极其活 跃。 | | | 港股通创新药概 | | --- | --- | --- | | 代码 | 名称 | 涨幅 (%) | | 159217 | 港股通创新药ETF工银 | 5.23 | | 513780 | 港股创新药50ETF | 4.98 | | 513120 | 港股创新药ETF | 4.83 | | 159316 | 恒生创新药ETF | 4.82 | | 159570 | 港股通创新药ETF | 4.81 | | 520700 | 港股创新药ETF基金 | 4.71 | | 520500 | 恒生创新药ETF | 4.41 | | 159567 | 港股创新药ETF | 4.31 | ETF份额变化方面，港股通创新药相关ETF今年整体份额出现增加，港股通创新药ETF（159570）和港股创新药ETF（159567）年内份额分别增加了20.68亿 份和9.19亿份，年内份额变动率均超过200%。 从投资逻辑来看，特朗 ...

Market Overview - The A-share market showed a slight upward trend with major indices closing in the green, including the Shanghai Composite Index up by 0.38% and the Shenzhen Component Index up by 0.79% [2][3] - The total trading volume in the market reached 752.2 billion CNY, with over 3,600 stocks rising [2] Sector Performance - The consumer sector experienced significant gains, particularly in leisure goods, office supplies, beauty care, pet economy, innovative pharmaceuticals, and food industries, while sectors like ports, shipping, and chemical fibers saw declines [4][12] - The beauty care sector led the market, with stocks like Kela Co., Yiyi Co., and Lafang Home Care hitting the daily limit [6][12] Notable Stocks - Kela Co. saw a price increase of 20.03%, closing at 16.12 CNY, while Yiyi Co. and Lafang Home Care also reached their daily limits [6][10] - The pet economy stocks surged, with Tianyuan Pet hitting the daily limit for two consecutive days, reaching a historical high [10][11] Pharmaceutical Sector - The pharmaceutical and biotech sectors showed strong performance, with stocks like Sanofi and Yipin Hong hitting the daily limit [13][14] - Sanofi's stock rose by 19.99%, closing at 39.37 CNY, following a licensing agreement with Pfizer for a dual-target antibody product [17] Hong Kong Market - In the Hong Kong market, CATL's stock rose by over 18%, closing at 307.6 HKD, with a total market capitalization of 1.39 trillion HKD [18][19] - CATL's dual listing in Hong Kong is expected to attract both domestic and international capital, supporting its global expansion and technological development [19]

Group 1 - The core viewpoint of the news highlights the positive movement in the pharmaceutical sector, particularly with the rise of the ChiNext Pharmaceutical ETF and the implications of new regulatory policies [1] - The "Medical Device Network Sales Quality Management Specification" was released on May 9, outlining responsibilities and quality management requirements for online sales operators and e-commerce platforms [1] - On May 20, 2023, 3SBio announced an exclusive licensing agreement with Pfizer for its self-developed PD-1/VEGF bispecific antibody SSGJ-707, which includes an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] Group 2 - Huayuan Securities noted that the pharmaceutical and biotechnology industry is showing multiple bottom characteristics, with policy impacts gradually adjusting and valuations at historical lows [2] - The innovation sector is gaining momentum, with companies like Heng Rui Medicine and Hansoh Pharmaceutical completing their innovation transformations and significantly increasing R&D investments post-2020 [2] - The aging population is accelerating the demand for chronic disease management, positioning the silver economy as a long-term growth opportunity [2]

Group 1 - A-shares indices collectively rose on May 20, with the pharmaceutical sector showing strong performance, particularly in biopharmaceutical ETFs which saw a 2.31% increase and a trading volume exceeding 1.57 billion yuan [1] - Notable stocks included Rongchang Bio, which rose over 9%, and Huaxi Bio and Tigermed, both increasing over 5% [1] - The Innovative Drug ETF also experienced a 2.26% rise, with a trading volume exceeding 2.73 million yuan, and significant gains from stocks like Huahai Pharmaceutical and Hansoh Pharmaceutical [1] Group 2 - Three Life Health signed a licensing agreement with Pfizer for a bispecific antibody product, which includes a non-refundable upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] - The agreement also includes a double-digit percentage sales revenue share based on product sales in authorized regions, and Pfizer will purchase $100 million worth of common stock from Three Life Health [1] - The ASCO annual meeting in 2025 is set to take place in Chicago, recognized as a major oncology academic conference [2] Group 3 - The market is shifting focus from earnings to fundamental changes in the industry and companies as it enters a performance vacuum period in May [3] - The innovative drug sector is expected to be a key investment theme for 2025, with significant research and development progress and resilience against trade wars [3] - The biopharmaceutical industry is anticipated to face significant differentiation by 2025, with the innovative drug sector entering a rapid growth phase, while the vaccine sector remains under pressure due to weak market demand and increased competition [3]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong performance, with the CSI Hong Kong Stock Connect Medical Theme Index rising by 1.93% on May 20, 2023 [1] - Notable stock performances include CSPC Pharmaceutical Group increasing over 8%, and other companies like Sinopharm, Hansoh Pharmaceutical, and others rising over 6% [1] - The Hong Kong Medical ETF (159366) also saw a rise of 2.33%, with a trading volume of 10.5768 million yuan, reflecting the overall performance of listed companies in the medical field [1] Group 2 - Haitong International predicts a significant turning point for the Hong Kong medical industry by 2025, driven by stricter regulatory policies and accelerated review and approval processes for innovative drugs and medical devices [2] - The implementation of the "filing system" for medical representatives and the "licensing system" for doctors is expected to shift marketing behaviors towards compliance and academic focus, increasing the demand for digital marketing, with the digital medical marketing market projected to reach 20-40 billion yuan by 2025 [2] - The approval of 48 innovative drugs and 65 innovative medical devices by the National Medical Products Administration in 2024 is anticipated to boost the number of new products and drive industry innovation [2] Group 3 - Guosen Securities also anticipates a significant turning point for the Hong Kong medical industry by 2025, driven by policy incentives and breakthroughs in innovative technologies [3] - The acceleration of the review and approval process for innovative drugs and medical devices is expected to further enhance industry innovation, with 48 innovative drugs and 65 innovative medical devices approved in 2024 [3] - The deepening application of AI technology in the medical field, supported by policies for the construction of innovative platforms, is expected to significantly improve industry efficiency, particularly in cost reduction and precision medicine [3]

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong upward trend, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 2.76% as of May 20, 2025 [1] - Notable individual stock performances include a 6.73% increase in CSPC Pharmaceutical Group and a 6.67% rise in Innovent Biologics [1] - The Hong Kong Medical ETF has seen a cumulative increase of 3.51% over the past week, reflecting positive market sentiment [1] Group 2 - Three-Sixty Biopharma's stock surged over 30% after announcing an exclusive global licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, with an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] - The licensing agreement includes a double-digit percentage royalty on net sales in licensed regions, and Pfizer may also subscribe to $100 million in new shares of Three-Sixty Biopharma [1] - Analysts expect a shift in market focus from earnings to fundamental changes in the industry and companies starting in May, with a continued positive outlook on innovative drugs and companies expanding into emerging markets [2] Group 3 - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of 50 highly liquid and large-cap healthcare companies, with the top ten stocks accounting for 60.54% of the index [2]

Group 1 - The Hong Kong stock market opened strong on May 20, with the Hong Kong Innovation Drug ETF (159570) rising over 3.6% and quickly surpassing a transaction volume of 4 billion [1] - The Hong Kong Innovation Drug ETF has seen a net inflow of over 2.2 billion in the last 60 days, indicating strong investor interest in the innovative drug sector [1] - On May 20, 2023, 3SBio announced a partnership with Pfizer, granting exclusive rights for the global development, production, and commercialization of its proprietary PD-1/VEGF bispecific antibody SSGJ-707 outside of mainland China [1] Group 2 - According to the agreement, 3SBio will receive a non-refundable upfront payment of $1.25 billion and up to $4.8 billion in milestone payments related to development, regulatory approval, and sales [1] - 3SBio will also receive a tiered sales royalty based on product sales in the licensed territories, and Pfizer will purchase $100 million worth of common stock in 3SBio upon the agreement's effective date [1] - The majority of the popular component stocks in the Hong Kong Innovation Drug ETF saw gains, with 3SBio rising over 30% [3] Group 3 - The 2025 ASCO Annual Meeting, recognized as a major oncology conference, will take place from May 30 to June 3, 2025, in Chicago, Illinois [3] - Several innovative drug companies are expected to disclose significant data at the ASCO meeting, with 3SBio set to present Phase 2 data for SSGJ-707 in non-small cell lung cancer [3] - The recent U.S. drug price reduction executive order may lead to global pharmaceutical companies adjusting their pricing strategies, with China's innovative drugs potentially becoming a preferred choice for business development transactions [4][5] Group 4 - The U.S. executive order aims to provide the best price for prescription drugs, but its short-term impact on innovative drug prices is expected to be limited due to the lack of implementation details and potential legal challenges [5] - Long-term pressures on U.S. drug prices are anticipated as Medicare and Medicaid expenditures are projected to grow from $1.5 trillion to $2.0 trillion from 2020 to 2024, with an annual growth rate of 7.0% [5] - The Hong Kong Innovation Drug ETF (159570) has a high concentration in innovative drugs, with over 85% of its weight in innovative drug stocks, making it a prominent player in the market [6]